Anupam Rasayan India Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2wc771qzary3surldeio6giy.pdf

Key Takeaways


Fluorination: The Next Growth Cycle

Anand Desai: "We understand that there is a time lag to introducing these products, but we have been working on these products since last three, four years. It is only that the customers had asked us to start the business only once the Tanfac acquisition was in place, which is there now, and this is how the business has started."

Europe+1: Structural Demand Shift

Vishal Thakkar: "this is a product, which is coming straight out of Europe to our portfolio, and we could do it in a very short time period. And that's where we were and Europe+1 movement of strategy or whatever, we want to call it as, that has now started playing out."

Product Pipeline & Commercialization


Financial Health & Margins

Vishal Thakkar: "We are fully funded. In fact, I will be generating more cash out of my business because if you look at it, I'm fairly funded on the day one. We will need no debt to grow, do the capex that we have budgeted for now."

Revenue Growth & Demand Visibility

Vishal Thakkar: "we have a visibility, the contracts have a business and the volume is practically there and it's about the price that we revise every six and 12 months as the case maybe."

Tanfac Integration & Outlook


Guidance & Commitments

CommitmentSpecificsTimeline
Standalone revenue growth25%+ on Anupam standalone basis (Tanfac over and above)FY24
Fluorination pipeline revenue$220–260 mn totalNext 3–5 years
LOI/contract revenue rampAt least ₹200 crores in FY24, ~₹475 crores in FY25FY24 / FY25
Product launches3–5 products in Q4 FY23; 6–8 molecules every year thereafterQ4 FY23 / annual
FY24 capex~₹300 croresFY24
Subsequent capex~₹250 croresNext 18–24 months
Working capital days~200 days and belowNext 3–5 quarters
FY23 annual revenue growthAt least 300–400 bps above 9M figure of 21% (~24–25%)FY23

Key Metrics

MetricQ3 FY23
Consolidated operating revenue₹382.7 cr, up 44% YoY (Q3 FY22 base did not include Tanfac)
Standalone operating revenue₹286.2 cr, up 7.5% YoY
Consolidated EBITDA₹108 cr, up 35% YoY
Consolidated EBITDA margin28%, lower due to Tanfac's lower margin profile
Standalone EBITDA margin29%
Consolidated PAT₹54.4 cr, up 44% YoY
Standalone PAT₹38.6 cr, up 2% YoY
Operating cash flow (quarter)₹57 cr, higher than PAT for the quarter
Operating cash flow (9 months)₹155 cr
Life Sciences segment share82% of total revenue, ~₹231 cr
Exports share62% of total revenue
Top 10 customer concentration91% of total revenue, across 24 products
Revenue loss from plant unavailability~₹45 cr in Q3; potential further loss of ₹5–10 cr in Q4
Products commercialized under LOIs/contracts (cumulative)4 core products; total product tally reached 50
Products planned for Q4 commercialization5 products, majority in fluorination chemistry
Revenue from FY22 LOIs/contracts (9 months)₹75–80 cr; expected to ramp to ₹200+ cr in FY24 and full ₹475 cr in FY25
Fluorination revenue opportunity$220–260 mn annual revenue over next 3–5 years
FY24 capex guidance₹300 cr; additional ₹250 cr in the following year
FY23 capex guidance₹170–175 cr; ₹100 cr deployed in 9 months
Contracted revenue on 6-month billing~60%